ENGLISH 邮件系统
  • 学术动态

第三十七期至真讲坛-美国俄亥俄州立大学常凌乾博士学术报告通知
作者:系统管理员 发布日期:2016-04-11 浏览次数:2239

报告题目:Nano-Electroporation Chips for Controllable Cell Reprogramming and Intracellular Sensing 

报告时间:2016418日(周一)上午10:00

报告地点:邵科馆一楼接待室

报告人:常凌乾 博士

邀请人:高分子材料与工程研究所  陈枫 副教授

 

报告人简介:

常凌乾博士,19869月出生。2008年在大连理工大学电子工程系获得学士学位;2011年在中科院电子所传感技术国家重点实验室获得硕士学位;2016年初在美国俄亥俄州立大学(The Ohio State University)生物医学工程系获得博士学位。研究领域主要包括,Micro-/Nano-fabrication, Micro-/Nano-scale Bio-chip, Biosensors. Nature Nanotechnology, Nano Letters, Small, Nanoscale, Lab Chip等学术期刊上发表论文35篇(含在审论文),其中第一作者/通讯作者论文共14篇(IF > 10论文3篇,IF > 5论文9篇),并撰写英文专著一章。担任SCI期刊Computer in Biology and Medicine编委和European Journal of Biomedical Research副主编,并担任ACS Applied Materials & Interfaces, Sensors and Actuators B: Chemical, Nanotechnology, Materials Science and Engineering C等十几个学术期刊审稿人。曾获2011University Fellowship (Ohio State University), 2012 – 2014National Science Foundation (NSF) Fellowship, 以及2015Ohio State University博士研究生最高奖Presidential Fellowship.

 

报告内容简述:

Electroporation is one of the most commonly used physical techniques for gene /drug delivery. However, conventional bulk electroporation (BEP) usually results in significantly cellular damage, low efficiency and total stochastic transfection yields at the single-cell level. Recent advances in nanofabrication enable powerful nanoscale electroporation devices that offered remarkable advantages over BEPs. This talk presents a novel nanochannel-based electroporation technique that offers unique performance in benign and precise gene delivery into living cells both in vitro and in vivo. The challenges, designs and fabrication strategies behind the nanochannel devices are discussed in details. A versatile nanoscale platform, in combination of cellular manipulation technologies, is implemented to position, pattern and genetic manipulation of living cells. This high-throughput nano-electroporation systems show great potentials in deterministic cell reprogramming, efficient adoptive immunotherapy and intracellular sensing of living cancer stem cells based on molecular beacon/siRNA/mRNA delivery.